Form 8-K - Current report:
SEC Accession No. 0001628280-26-033856
Filing Date
2026-05-12
Accepted
2026-05-12 07:01:41
Documents
12
Period of Report
2026-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ird-20260512.htm   iXBRL 8-K 26290
2 EX-99.1 ird-2026512xex991.htm EX-99.1 81324
  Complete submission text file 0001628280-26-033856.txt   234144

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ird-20260512.xsd EX-101.SCH 1839
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ird-20260512_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ird-20260512_pre.xml EX-101.PRE 12568
15 EXTRACTED XBRL INSTANCE DOCUMENT ird-20260512_htm.xml XML 2994
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 26965814
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)